	2012 Mar 31	C 2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR
Total Revenue	346	327	395	443	606	684	848	1,039	1,179	1,362	1,413	1,421	1,370	1,551	3,420
Cost of Operating Revenue	246	252	263	289	393	425	538	630	702	802	845	962	873	920	1,796
Gross Profit	100	75	132	154	213	258	310	409	477	559	568	459	496	631	1,624
Gross Margin	28.9	23.0	33.5	34.7	35.2	37.8	36.5	39.4	40.5	41.1	40.2	32.3	36.2	40.7	47.5
Total Operating Expenses	317	360	406	454	594	665	802	949	1,054	1,196	1,355	1,436	1,346	1,451	-
Operating Profit	29	-33	-11	-11	12	18	46	91	125	166	58	-15	23	101	-
Operating Margin	8.4	-10.0	-2.7	-2.4	2.0	2.7	5.4	8.7	10.6	12.2	4.1	-1.1	1.7	6.5	-
Financing Income/(Expense) - Net	-43	-41	-42	-41	-34	-40	-31	-38	-34	-24	-16	-61	-71	-63	-71
Profit before Taxes	-5	-73	-110	-63	-15	-14	24	59	94	137	53	-138	-55	44	349
Income Taxes	-4	-8	1	3	3	-1	13	2	12	32	8	-16	-25	12	249
Profit after Tax	-1	-65	-110	-11	-18	-14	422	49	70	95	41	-121	-36	22	-
PAT Margin	-0.4	-19.8	-28.0	-2.4	-3.0	-2.0	49.7	4.7	5.9	7.0	2.9	-8.5	-2.6	1.4	-
EPS - Basic - ex Extraordinary Items	-0.13	-5.70	-8.54	-4.59	-0.96	-0.47	0.04	2.00	2.87	3.87	1.65	-4.88	-1.44	0.88	-
EPS - Diluted - ex Extraordinary Items	-0.13	-5.70	-8.54	-4.59	-0.96	-0.47	0.04	1.99	2.85	3.85	1.65	-4.88	-1.44	0.85	-
EBIT	29	-33	-11	-11	12	18	46	91	125	166	58	-15	23	101	421
EBITDA	53	-4	22	21	68	60	88	133	176	216	109	40	85	167	654
EBITDA Margin	15.3	-1.2	5.5	4.8	11.3	8.7	10.3	12.8	14.9	15.9	7.7	2.8	6.2	10.8	19.1

Balance Sheet

Abridged

Understanding Balance Sheet

Viyash Scientific Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	207	228	263	319	491	728	538	600	704	714	783	790	823	874	2,255
Long-Term Investments	0	2	0	0	0	0	0	0	0	0	7	7	1	0	-1,020
Property Plant & Equipment - Net	246	270	256	380	429	401	227	244	356	348	326	352	311	299	1,272
Total Non-Current Assets	341	358	360	686	1,038	1,177	805	788	759	679	668	739	718	728	2,374
Total Assets	547	586	623	1,005	1,528	1,905	1,343	1,388	1,463	1,393	1,451	1,529	1,540	1,602	4,628
Total Current Liabilities	326	342	402	442	290	664	431	434	495	461	512	526	627	505	946
Long Term Debt	81	138	151	247	211	165	110	152	203	139	164	220	172	300	149
Total Non-Current Liabilities	94	144	159	310	290	247	227	207	236	155	199	254	200	327	568
Total Liabilities	419	487	561	752	580	911	658	641	731	616	711	780	827	832	1,514
Total Shareholders' Equity	123	95	57	127	946	977	648	707	687	728	692	699	657	704	2,911
Minority Interest	5	5	5	125	2	17	37	40	45	49	48	50	56	66	204
Total Equity	128	100	61	253	948	994	685	747	732	776	740	749	713	770	3,115
Total Liabilities & Equity	547	586	623	1,005	1,528	1,905	1,343	1,388	1,463	1,393	1,451	1,529	1,540	1,602	4,628

Cash Flow

Abridged

Understanding Cash Flow Statement

Viyash Scientific Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	14.05	-35.93	-17.73	-16.65	35.30	63.21	96.10	119.76	147.27	164.51	104.11	34.08	31.49	122.93	652.08
Working Capital - Increase/(Decrease)	-17.29	2.49	-67.45	-53.98	-71.46	-104.37	-77.87	-27.94	-58.30	-70.89	-89.30	-51.61	-45.67	-88.38	-329.16
Net CF from Operating Activities	-3.25	-33.44	-85.18	-70.64	-36.16	-41.16	18.23	91.81	88.98	93.63	14.81	-17.53	-14.18	34.55	332.69
Capital Expenditures - Net	69.90	54.30	81.31	86.38	63.20	75.13	44.91	23.51	40.00	44.57	31.27	74.51	16.46	30.77	94.97
Net CF from Investing Activities	-69.59	-55.79	-80.79	-156.17	-320.15	-119.00	1.34	-69.92	-78.97	8.02	-95.99	-66.19	-6.49	-27.24	-93.89
Dividends Paid - Cash - Total	3.29	-	-	-	-	-	4.85	-	4.86	1.43	12.34	-	-	-	-
Stock - Issuance/(Retirement) - Net	0.11	25.36	42.86	150.73	540.01	40.54	0.71	0.67	2.10	10.45	11.25	-	-	7.45	-
Debt - LT & ST - Issuance/(Retirement) - Total	89.29	27.65	115.27	55.89	-199.09	143.69	-17.20	6.23	-4.02	-125.04	86.24	68.10	43.98	-15.05	-
Net Cash Flow from Financing Activities	90.10	64.89	186.78	227.98	349.12	184.23	-24.12	6.35	-9.70	-116.00	83.47	67.80	43.91	-9.46	-
Free Cash Flow to Equity	16.14	-60.09	-51.22	-101.13	-298.45	27.40	-43.88	74.53	44.96	-75.98	69.77	-23.94	13.34	-11.28	237.72
Free Operating CF net dividend	-88.40	-89.93	-170.92	-161.57	-101.70	-119.91	-33.64	66.37	43.40	39.37	-30.00	-103.71	-49.79	-5.92	197.96
Free Operating CF	-85.11	-89.93	-170.92	-161.57	-101.70	-119.91	-28.79	66.37	48.26	40.80	-17.66	-103.71	-49.79	-5.92	197.96

Business Segment Analysis

FY End:

Mar 25

Viyash Scientific Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 40.47 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 1,551.37 Cr

Assets

Pharmaceuticals (100.0%)₹ 1,601.95 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 100.74 Cr

Regional Segment Analysis

FY End:

Mar 25

Viyash Scientific Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Europe (45.1%)₹ 700.20 CrAsia (28.7%)₹ 444.95 CrRest of the world (26.2%)₹ 406.23 Cr

Assets

Asia (40.2%)₹ 643.70 CrEurope (31.9%)₹ 511.47 CrRest of the world (20.8%)₹ 333.87 CrUnallocated (7.0%)₹ 112.91 Cr

Historical Segment Analysis

Track how Viyash Scientific Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	30	51	90	47	41	236	32	86	36	40
Analytical Services	1	2	0	1	1	4	-	-	-	-
Inter Segment	0	-	-	-	-	-	-	-	-	-
Speciality Chemicals	1	5	2	1	1	0	-	-	-	-

Frequently Asked Questions

What is the revenue of Viyash Scientific Ltd.?

The latest trailing twelve month revenue of Viyash Scientific Ltd. is ₹ 3,420.31 Cr, reflecting a 1-year growth of 120.47% and a 3-year CAGR of 34.02%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Viyash Scientific Ltd.?

The latest trailing twelve month net profit (PAT) of Viyash Scientific Ltd. is ₹ 177.28 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Viyash Scientific Ltd.?

The trailing twelve month EBITDA of Viyash Scientific Ltd. is approximately ₹ 420.59 Cr (based on an operating margin of 12.30%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Viyash Scientific Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Viyash Scientific Ltd. is 4.01. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Viyash Scientific Ltd.?

The debt-to-equity ratio of Viyash Scientific Ltd. stands at 0.17. The interest coverage ratio is 6.08x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Viyash Scientific Ltd.?

The estimated book value per share of Viyash Scientific Ltd. is 66.70 (derived from a P/B ratio of 4.03 and market price of ₹ 268.65), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Viyash Scientific Ltd.?

The trailing twelve month operating cash flow of Viyash Scientific Ltd. is ₹ 263.66 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Viyash Scientific Ltd. report consolidated or standalone financials?

Viyash Scientific Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.